Literature DB >> 2924374

Effect on liver tumor growth in rats of allopurinol and 5-fluorouracil in combination with hepatic artery ligation.

G Carlsson1, B Gustavsson, L Hafström.   

Abstract

Rats with an experimental solitary liver tumor of a nitrosoguanidine-induced colonic adenocarcinoma were subjected to hepatic artery ligation (HAL) alone or in combination with 5-fluorouracil (5-FU) in three different doses, with or without the addition of allopurinol. The drugs were injected i.p. on 3 consecutive days before or after the HAL procedure. HAL alone significantly reduced the tumor growth compared with the control procedure (P less than 0.001). This observation was correlated with a significantly prolonged survival for the ligated animals (P less than 0.01). The administration of a low dose of 5-FU (15 mg/kg per day) in combination with allopurinol (100 mg/kg per day) enhanced tumor growth compared with that in animals treated with 5-FU only (P less than 0.01) or nontreated animals (P less than 0.05). A significant increase in survival was observed in animals given a high dose of 5-FU (60 mg/kg per day) after HAL compared with non-treated animals (P less than 0.001) as well as animals subjected to HAL alone (P less than 0.02). All animals receiving more than 15 mg/kg per day 5-FU before HAL succumbed within 10 days. The addition of allopurinol did not protect the animals against this mortality. These observations indicate that the effect of HAL followed by 5-FU is dose-dependent and that, at least in this treatment modality, allopurinol does not modulate the toxicity of 5-FU.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2924374     DOI: 10.1007/BF00267949

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  31 in total

1.  A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil.

Authors:  W D Ensminger; A Rosowsky; V Raso; D C Levin; M Glode; S Come; G Steele; E Frei
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

2.  Cross-reacting tumor-associated antigen (s) among chemically induced rat colon carcinomas.

Authors:  G Steele; H O Sjögren
Journal:  Cancer Res       Date:  1974-08       Impact factor: 12.701

3.  Serum enzyme changes after hepatic dearterialization in man.

Authors:  O Almersjö; S Bengmark; L Engevik; L O Hafström; B P Loughridge; L A Nilsson
Journal:  Ann Surg       Date:  1968-01       Impact factor: 12.969

4.  Influence of hepatic artery ligation on survival. An experimental study in rats.

Authors:  L Hafström; G Carlsson
Journal:  Am J Surg       Date:  1984-05       Impact factor: 2.565

5.  Allopurinol modulation of high-dose fluorouracil toxicity.

Authors:  R M Fox; R L Woods; H N Tattersall; G W Brodie
Journal:  Cancer Treat Rev       Date:  1979-06       Impact factor: 12.111

Review 6.  On the nature of thymineless death.

Authors:  S S Cohen
Journal:  Ann N Y Acad Sci       Date:  1971-11-30       Impact factor: 5.691

7.  Cytotoxic perfusion for colorectal liver metastases.

Authors:  I Taylor
Journal:  Br J Surg       Date:  1978-02       Impact factor: 6.939

8.  Intravesical high dose 5-fluorouracil instillations combined with allopurinol--a therapeutic alternative in the treatment of multiple bladder tumors.

Authors:  K H Leissner; B Gustavsson
Journal:  J Urol       Date:  1984-07       Impact factor: 7.450

9.  Resection of hepatic metastases from colorectal cancer.

Authors:  M A Adson; J A van Heerden; M H Adson; J S Wagner; D M Ilstrup
Journal:  Arch Surg       Date:  1984-06

10.  Phase I-II trial of high-dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer.

Authors:  S Madajewicz; N Petrelli; Y M Rustum; J Campbell; L Herrera; A Mittelman; A Perry; P J Creaven
Journal:  Cancer Res       Date:  1984-10       Impact factor: 12.701

View more
  1 in total

1.  Organ distribution and antitumor activity of free and liposomal doxorubicin injected into the hepatic artery.

Authors:  Y Zou; I Horikoshi; T Kasagi; X Gu; R Perez-Soler
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.